Bone density effects of continuous estrone sulfate and varying doses of medroxyprogesterone acetate

Obstetrics and Gynecology

Volumn 93, Issue 6, 1999, Pages 1009-1013

  Nand, Swaran L ^a,d   Wren, Barry G ^b   Gross, Barbara A ^c   Heller, Gillian Z ^d   Webster, M ^e   Baber, R ^a   Moreton, T ^a   Burger, H ^b   Silberberg, S ^c   Leahy, F ^d   O'Connor, V ^e   Smith, H ^a   Hangan, ^b   Roxburgh, D ^d   Penon, D ^b   Eden, J ^c   Detmold, N ^a   Ayton, R ^b   Darling, G ^d   MacLennan, A H ^e   Wenzel, S ^b   more..

^a Ogen/Provera Study Group   (Australia)

^b School of Obstetrics and Gynaecology   (Australia)

^c Sydney Menopause Centre   (Australia)

^d ROYAL HOSPITAL FOR WOMEN   (Australia)

^e MACQUARIE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRONE SULFATE; MEDROXYPROGESTERONE ACETATE; PIPERAZINE ESTRONE SULFATE;

ADULT; ARTICLE; BONE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HORMONE SUBSTITUTION; HUMAN; LUMBAR SPINE; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; BONE DENSITY; DOUBLE-BLIND METHOD; ESTROGENS, CONJUGATED (USP); ESTRONE; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; PROGESTERONE CONGENERS;

EID: 0032997626     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(98)00560-2     Document Type: Article

References (23)

1. Cauley JA, Seeley DO, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research group. Ann Intern Med 1995;122:9-16.
2. Session DR, Kelly AC, Jewelewicz R. Current concepts in estrogen replacement therapy in the menopause. Fertil Steril 1993;59:277-84.
3. Lindsay R, Cosman F. Estrogen in prevention and treatment of osteoporosis. Ann N Y Acad Sei 1990;592:326-33.
4. Riggs BL, Melton LJ III. Involutional osteoporosis. N Engl J Med 1986;314:1676-86.
5. Magos AL, Brincat M, Studd JW, Wardle P, Schlesinger P, O'Dowd T. Amenorrhea and endometrial atrophy with continuous oral oestrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1985;65:496-9.
6. Weinstein L, Bewtra C, Gallagher JC. Evaluation of continuous low dose regimen of estrogen progestin for treatment of the menopausal patient. Am J Obstet Gynecol 1990;162:1534-42.
7. Eiken P, Kolthoff N, Nielsen SP. Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women. Bone 1996;19:191S-3S.
8. Harris ST, Genant HK, Baylink DJ, Gallagher JC, Karp SK, McConnell MA, et al. The effects of estrone (Ogen) on spinal bone density of postmenopausal women. Arch Intern Med 1991;151:1980-4.
9. Genant HK, Baylink D, Gallagher JC, Harris ST, Steiger P, Herber M. Effect of estrone sulphate on postmenopausal bone loss. Obstet Gynecol 1990,76:579-84.
10. Nand SL, Webster MA, Baber R, O'Connor V. Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy. The Ogen/Provera Study Group. Obstet Gynecol 1998;91:678-84.
11. Nand SL, Webster MA, Baber R, Heller GZ. Menopausal symptom control and side effects on continuous estrone sulfate and three doses of medroxyprogesterone acetate. The Ogen-Provera Study Group. Climacteric 1998;1:1-8.
12. Genant HK, Grampp S, Gluer CC, Faulkner KG, Jergas M, Engelke K, et al. Universal standardization for dual X-ray absorptiometry: Patient and phantom cross-calibration results. J Bone Miner Res 1994;9:1503-14.
13. Goodman LA, Kruskal WH. Measures of association for cross-classification. IV. J Am Stat Assoc 1972;67:415-21.
14. Diggle PJ, Liang KY, Zeger SL. Analysis of longitudinal data. Oxford: Oxford University Press, 1994.
15. Milliken GA, Johnson DE. Analysis of messy data. Vol. I: Designed experiments. New York: Van Nostrand Reinhold Co, 1984.
16. Abdalla H, Hart DM, Lindsay R, Leggate I, Hooke A. Prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet Gynecol 1985;6:789-92.
17. The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density. JAMA 1996;276:1389-96.
18. Christiansen C, Christiansen MS, McNair P, Hagen C, Stocklund KE, Transbol I. Prevention of early postmenopausal bone loss: Controlled 2-year study in 315 normal females. Eur J Clin Invest 1980;10:273-9.
19. Christiansen C, Riis BJ. Hormonal replacement therapy and the skeletal system. Maturitas 1990;12:247-57.
20. Jensen J, Christiansen C, Rotbro P. Cigarette smoking, serum estrogens, and bone loss during hormone replacement therapy early after menopause. N Engl J Med 1985;313:973-5.
21. Keil DP, Baron JA, Anderson JJ, Hannan MT, Felson DT. Smoking eliminates the protective effect of oral estrogens on the risk of hip fracture among women. Ann Intern Med 1992;116:716-21.
22. Gallagher CJ, Kable WT, Goldgar D. Effect of progestin therapy on cortical and trabecular bone: Comparison with estrogen. Am J Med 1991,-90:171-8.
23. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 1979;74:829-36.